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Abstract: In mammals, DNA methylation is necessary for the maintenance of genomic stability, gene
expression regulation, and other processes. During malignant diseases progression, changes in both
DNA methylation patterns and DNA methyltransferase (MTase) genes are observed. Human de
novo MTase DNMT3A is most frequently mutated in acute myeloid leukemia (AML) with a striking
prevalence of R882H mutation, which has been extensively studied. Here, we investigate the functional
role of the missense mutations (S714C, R635W, R736H, R771L, P777R, and F752V) found in the catalytic
domain of DNMT3A in AML patients. These were accordingly mutated in the murine Dnmt3a catalytic
domain (S124C, R45W, R146H, R181L, P187R, and F162V) and in addition, one-site CpG-containing
DNA substrates were used as a model system. The 3–15-fold decrease (S124C and P187R) or complete
loss (F162V, R45W, and R146H) of Dnmt3a-CD methylation activity was observed. Remarkably, Pro 187
and Arg 146 are not located at or near the Dnmt3a functional motives. Regulatory protein Dnmt3L
did not enhance the methylation activity of R45W, R146H, P187R, and F162V mutants. The key steps
of the Dnmt3a-mediated methylation mechanism, including DNA binding and transient covalent
intermediate formation, were examined. There was a complete loss of DNA-binding affinity for
R45W located in the AdoMet binding region and for R146H. Dnmt3a mutants studied in vitro suggest
functional impairment of DNMT3A during pathogenesis.
Keywords: DNA methyltransferase Dnmt3a; missense mutations; leukemia; DNA methylation;
S-adenosyl-l-methionine; DNA-protein binding
1. Introduction
DNA methylation is an important epigenetic modification essential for the regulation of cell
processes in both eukaryotes and prokaryotes. In eukaryotes, DNA methylation is necessary for
the maintenance of genomic stability, gene expression regulation, and other processes [1,2]. DNA
methylation is maintained by DNA methyltransferases (MTases), which transfer a methyl group from
co-factor S-adenosyl-l-methionine (AdoMet) to the five positions of the cytosine residue mainly within
CpG dinucleotides [3]. Changes in the methylation process occur in various human pathologies [4].
During human cancer development, there are alterations in the pattern of methylation and multiple
disorders in the MTases, including missense mutations [4–7]. The function of mammalian Dnmt3a is to
methylate DNA de novo [3].
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According to the CBioPortal cancer clinical research database, DNMT3A missense mutations
account for 1.7% of all known DNMT3A abnormalities (215 studies, 56,243 patients). DNMT3A missense
mutations can be divided into two groups according to their localization and different disease types [4].
The first group includes mutations in the regulatory DNMT3A domain, which are most common in
the development of overgrowth syndrome with intellectual disability [8,9]. The second group includes
mutations in the catalytic domain, which are most characteristic in the development of acute myeloid
leukemia (AML) [10–15]. AML is the most common leukemia among adults, and the incidence is
increasing with aging [13]. Although the main cause of the disease is still unknown, some risk factors
have been identified, including mutations in DNMT3A gene [14].
The Preliminary Results
We have analyzed the DNMT3A expression among the different cancer types (Figure 1) using
the information of the recent clinical studies included in The Cancer Genome Atlas (TCGA) [15] and
CBioPortal database [16]. Interestingly, the maximum expression of DNMT3A connected to mutated
forms of DNMT3A was observed only in the case of AML patients with a wide range of levels of mRNA
encoding mutated DNMT3A. It should be noted, that in addition to the hyperexpression of the mutated
DNMT3A in AML cells, the aberrant methylation pattern also has been reported [17]. The exchange of
R882 to histidine (R882H) is the hotspot mutation during AML progression, which occurs in 60% of all
mutations [10]. It is the most well studied in terms of influence on human DNMT3A functioning [18].
R882H leads to an 80% loss of DNMT3A activity due to the inability of mutant DNMT3A to form active
tetramers with regulatory protein DNMT3L [18]. Notably, other mutations are spread throughout
DNMT3A in AML, although these occur at a lower frequency (Table 1 and Figure 1). To our knowledge,
there is very little information on how these mutations may impact the DNMT3A function.
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no mutation, white dots mark not sequenced samples, red triangles mark frameshifts and splicing
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Table 1. Frequency of different Dnmt3a-CD mutations occurred in acute myeloid leukemia (AML) based
on the research from OncoKB (Precision Oncology Knowledge Base), CBioPortal (The cBioPortal for
Cancer Genomics), TCGA (The Cancer Genome Atlas), and COSMIC (Catalogue of Somatic Mutations
In Cancer) databases and [12,19–27]. The selected amino acids are given in bold.
Amino Acid
Number in
Dnmt3a-CD
Amino Acid Number in
Full-Length Human
DNMT3A
The Number
of Patients
The Number
of COSMIC
References
Allele
Frequency
R45 R635W/Q 5 4 0.24
V46 V636M 2 2 -
S124 S714C 6 12 0.29
P128 P718L 1 1 -
R139 R729W/Q 3 5 0.11
Y145 Y735C 2 6 -
R146 R736H/C/A/P 10 10 0.49
F162 F752V 2 2 -
R181 R771Q/L 3 3 0.42
P187 P777R 2 1 -
B191 D781G 1 1 0.1
R202 R792H/C 2 2 0.41
K213 R803S 1 1 -
K251 K841Q 1 1 -
R292 R882H/C/P 173 619 0.28
A319 F909C 1 1 0.17
For several mutations that are located within the DNMT3A/3A and DNMT3A/3L interaction
interfaces, the disruption of the DNMT3A ability to form active tetramers and diverse levels of activity
was shown [18,28,29]. In addition, mutations of DNMT3A at its DNA binding residues decrease
methylation activity [30].
This study aimed to examine the functional consequences of the widespread AML missense
mutations found in the human DNMT3A catalytic domain. Therefore, we studied the murine Dnmt3a
catalytic domain, which is highly homologous to its human counterpart. We demonstrated in vitro
that substitutions of amino acid residues that do not belong to conserved motifs among MTases had
a strong impact on the methylation reaction. This will help to explain the disease phenotypes and
changes in the DNA methylation pattern observed in AML patients.
2. Materials and Methods
2.1. Chemicals, Oligonucleotides, and Enzymes
AdoMet and AdoHcy were from Sigma (St Louis, MO, USA). The buffers used were: A, 20 mM
HEPES, pH 7.5, 100 mM KCl, 1 mM EDTA, 1 mM 1,4-dithiothreitol; B, 8 mM phosphate, pH 7.4, 0.15 M
NaCl, 3 mM KCl, 0.5% Tween-20. Oligonucleotides (Table 2) were from Syntol (Moscow, Russia) with
the fluorescent label 6-carboxyfluorescein covalently attached to the 5′- end phosphate through the
aminoalkyl linker -NH-(CH2)6. Oligonucleotides containing 2-pirimidinone were synthesized by S.N.
Mikhailov. Restriction endonuclease Hin6I was from SibEnzyme (Novosibirsk, Russia).
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Table 2. DNA duplexes.
Designation Sequence *
fCG/GCf 5
′- FAM - CTGAATACTACTTGCGCTCTCTAACCTGAT
3′- GACTTATGATGAACGCGAGAGATTGGACTA - FAM
fCG/CG 5
′- FAM - CTGAATACTACTTGCGCTCTCTAACCTGAT
3′- GACTTATGATGAACGCGAGAGATTGGACTA
fCG/GZ 5
′- FAM - GAGCCAAGCGCACTCTGA
3′- CTCGGTTCGZGTGAGACT
fCG/GC 5
′- FAM - GAGCCAAGCGCACTCTGA
3′ - CTCGGTTCGCGTGAGACT
CGZ/GCf 5
′ - GAGCCAAGCGZACTCTGA
3′ - CTCGGTTCGCGTGAGACT - FAM
* FAM, f, 6-carboxyfluorescein; Z (2-pyrimidinone) and CG dinucleotides are written in bold. Target cytosine
residues are underlined.
2.2. Site-Directed Mutagenesis
Plasmid pET28a(+) carrying the catalytic part of the murine dnmt3a gene with the N-terminal
His6-tag was kindly provided by A. Jeltsch. All amino acid changes were introduced by site-directed
mutagenesis. The sequences of all mutated plasmids were checked by Sanger sequencing.
2.3. Protein Expression and Purification
Plasmid pET41b carrying the murine dnmt3l gene with N-terminal His8-tag and C-terminal
GST was kindly provided by G.L. Xu. The C-terminal GST was not removed during further protein
purification. All proteins were expressed in Escherichia coli BL21(DE3) strain (Stratagene, La Jolla, CA,
USA) and purified by metal-affinity chromatography on Co2+ Talon® resin (GE Healthcare, Chicago, IL,
USA) as previously described [31]. The proteins were analyzed in 12.5% PAG with 0.1% SDS, the purity
was >95%. Concentrations of the proteins were determined using the standard Bradford technique.
2.4. CD Spectroscopy
Circular dichroism measurements were performed on a Chira Scan spectrophotometer (Applied
Photophysics, Surrey, Leatherhead, UK) using a 1-mL cuvette with 0.5-mm path length in 1× buffer
A with 100 nM AdoHcy at 15 ◦C. All protein concentrations were about 0.5 g/L. The baseline was
recorded for buffer A in the presence of 100 nM AdoHcy. The spectra for each probe were measured
three times and then averaged.
2.5. Methylation Assay
WT and mutant Dnmt3a-CD activities were analyzed by the protection of the methylated DNA
from cleavage by restriction endonucleases [32]. The 30 bp fCG/GCf DNA substrate with two FAM
labels (Table 2), containing the CpG methylation site within G↓CGC Hin6I recognition site (the cleavage
position is indicated with an arrow) was used. Three hundred nanomolar fCG/GCf was methylated
with 2 µM WT Dnmt3a-CD or mutants in buffer A in the presence of 25 µM AdoMet at 37 ◦C.
The reaction was stopped by heating to 95 ◦C for 1 min. After methylation, fCG/GCf was digested
with Hin6I for 1 h at 37 ◦C in the same buffer with added Mg2+ (3 µM). DNA duplex fCG/GCf cleaved
without prior methylation was used as a control. Reaction mixtures were analyzed in 20% PAG with
7 M urea and visualized with a Typhoon FLA 9500 scanner (GE Healthcare, Chicago, Illinois, USA).
The fluorescence intensities of intact DNA and cleavage products were determined using GelAnalyzer
2010a software. The extent of DNA cleavage (ω) was calculated as a ratio of fluorescence intensity
of the cleaved DNA to the total fluorescence intensity of the intact and cleaved DNA. The extent of
methylation (M) was calculated using the equation:
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M =
ω0 − ωDnmt3a
ω0
× 100%, (1)
whereω0 andωDnmt3a are the extent of DNA cleavage without or after methylation [32].
The concentration of the methylated DNA [(CH3)-DNA], was calculated using the equation:
[(CH3)-DNA] = M × CDNA, (2)
where CDNA is the initial DNA duplex concentration.
To obtain time courses of the methylation, the test samples were taken from the reaction mixtures
after 1.5, 3, 4.5, 6, 7.5, 9, 15, 20, 40, 60, or 90 min. The initial slopes of the curves were determined by linear
regression, and the initial rates of methylation (v0) were calculated. Along with this, the methylation of
the fCG/GCf DNA substrate by WT and mutant Dnmt3a-CD during 2 h was performed, and M values
were calculated.
In addition, methylation of the fCG/GCf DNA substrate by WT or mutant Dnmt3a-CD in the
presence of Dnmt3L during 2 h was determined. Reaction mixtures contained 120 nM fCG/GCf, 1 µM
Dnmt3L, 1 µM WT or mutant Dnmt3a-CD, and 2.5 mM AdoMet in buffer A. The MTase and Dnmt3L
solutions were preincubated for 30 min at 37 ◦C, and then the reaction was started by the addition of
the other components to these solutions. Further analysis was conducted as described above.
2.6. Formation of Covalent Intermediates between Dnmt3a and DNA Duplexes Containing 2-Pyrimidinone
Three hundred micromolar DNA duplexes fCG/GZ and CGZ/GCf were incubated with 6 µM WT
Dnmt3a-CD or mutants in buffer A in the presence of 100 µM AdoHcy for 1 h at 4 ◦C. The reaction
mixtures were analyzed in 12% PAG with 0.1% SDS and were visualized as described above.
2.7. DNA Binding
WT Dnmt3a-CD or mutants binding to 30 bp fCG/CG DNA substrate (100 nM) with one FAM
label was studied using fluorescence polarization (P) in buffer A in the presence of 100 µM AdoHcy.
Measurements were performed using a Cary Eclipse spectrofluorometer (Varian, USA) with excitation
at 495 nm and emission at 520 nm at 25 ◦C in 120-µL cuvettes with a 1-cm pathlength, P was defined in
terms of the vertical (Iv) and horizontal (Ih) emission components as
P = (Iv − GIh)/(Iv + Ih), (3)
where G is the instrumental correction factor, which was measured once before each experiment. DNA
substrate was preincubated with AdoHcy, and fluorescence polarization of free fCG/CG (P0) was
measured. WT Dnmt3a-CD or mutants were added as 1–2 or 4–5 µL aliquots, respectively, up to
a final concentration 1.5–4 µM, and the P value of bound DNA was recorded after 2 min of incubation.
Dependences of P values on the total concentration of Dnmt3a-CD were obtained. The dissociation
constants (Kd) for the complexes were calculated by approximation of the obtained dependences using
the 3-parameter Hill equation:
P = P0 +
[E]n
[Kd]
n + [E]n
, (4)
where [E] is the Dnmt3a-CD concentration, n is the Hill coefficient.
2.8. Western Blotting
Probes containing 0.5 or 1 µg of R181L in buffer A were analyzed in 15% PAG with 10% SDS
and were transferred to the membrane using a Trans Blot Turbo Transfer System (Bio-Rad, Hercules,
California, USA) according to the instructions of the supplier. The membrane was blocked in milk,
washed in buffer B, incubated with 1:5000 mouse HRP monoclonal anti-His6-tag antibodies, and then
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with 1:15000 secondary antibodies. The membrane was scanned at ChemiDoc XRS+ system using the
Immune-Star HRP kit (Bio-Rad, Hercules, CA, USA) with a 5 s exposition.
2.9. Computational Modeling
DNA-(DNMT3A-CD)-DNMT3L complex structure was modeled using Chimera 1.10.2 software
based on PDB file 6F57 [30].
2.10. Database Analysis
The following databases describing cancer genetic changes were used to search for mutations
in dnmt3a gene associated with AML: OncoKB (Precision Oncology Knowledge Base), CBioPortal
(The cBioPortal for Cancer Genomics), TCGA (The Cancer Genome Atlas) and COSMIC (Catalogue of
Somatic Mutations In Cancer) with selection of AML and default search parameters. The number of
patients and COSMIC references along with allele frequency of the mutation were used as criteria for
the frequency determination. DNMT3A expression during different cancer types was analyzed with
CBioPortal tools based on the TCGA database information with default parameters.
3. Results
To identify the most common mutations in patients with AML, analysis of the missense mutations’
frequency occurrence in the DNMT3A catalytic domain was performed. It was based on the data [12,19–27]
extended with recent clinical studies data from cancer databases (Table 1). Mutations in the DNMT3A
catalytic domain indicated among a large number of patients (R635W/Q, S714C, and R736H/C/A/P)
were found. In addition, mutations of potential interest in terms of properties of the substituted amino
acid residues (Figure 2), even though they were not the widespread mutations, were identified (P777R,
R771L, and F752V). As a result, six amino acid exchanges S714C, R736H, R771L, R635W, P777R, and
F752V corresponding to murine S124C, R146H, R181L, R45W, P187R, and F162V were selected for further
research on their impact on Dnmt3a-CD functioning (Figure 2). According to COSMIC, all chosen
mutations lead to the development of cancer and practically do not occur in healthy cells. They have not
been previously studied in detail in terms of the effect on the murine Dnmt3a-CD.
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Figure 2. Alignment of the sequences of the catalytic domains of human and murine ethyltransferases
(MTases) Dnmt3a and Dnmt3b and prokaryotic MTases HhaI and HaeIII with underlined conserved
motives (I-X) [33] and location of mutated amino acid residues. The negatively charged amino acids
are given in red, the positively charged ones are given in blue, the polar ones are given in violet, the
aromatic/non-polar ones are given in green, proline is given in gray, cysteine is given in wine-red,
glycine is given in light orange, histidine is given in magenta. Highly conserved amino acids are given
stars above, conserved amino acids are given two dots above, often preserved amino acids are given
one dot above. The mutated amino acid residues are indicated.
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3.1. Dnmt3a-CD Purification
In this study, the murine Dnmt3a-CD was used to evaluate the effects of mutations observed in
human DNMT3A. Murine Dnmt3a-CD is easier to purify, has an identical primary structure to the
human enzyme, and can function without the regulatory part [3], which makes it an excellent model
system to study DNMT3A functioning.
The WT and mutant Dnmt3a-CD were expressed in E. coli as C-terminal His6-proteins and purified
by metal affinity chromatography. The concentration of WT (37 kDa), S124C, and R45W was 12–38 µM.
The concentration of mutants P187R and F162V was only 2–3 µM, probably due to their weak expression.
In the case of R181L, the second fraction with molecular mass 20 kDa was observed. Western blot analysis
with His6-tag antibodies showed the absence of His6-tag in the low-mass fraction (Figure A1). Mass
spectra analysis showed the N-terminal fragments of Dnmt3a-CD in the low-mass fraction (data not
shown). No further studies have been conducted with this mutant.
The CD spectra of WT Dnmt3a-CD and mutant enzymes (Figure 3) did not reveal remarkable
changes in the secondary structure distribution. This result indicates that all the mutant proteins were
properly folded. Judging by the ellipticity values at 222 nm, the α-helical content in the mutants,
apparently, had not changed. Small differences were observed only in the case of the P187R, which
may indicate a slight disturbance of the α-helix percent.
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DNA substrate fCG/GCf (Table 2). The methylation activity of Dnmt3a-CD was measured by the
protection of methylated DNA from cleavage by restriction endonuclease Hin6I [32]. This allowed
us to avoid measuring the amount of tritium incorporated into oligonucleotide duplexes used in
traditional methylation assay [31]. Thirty base pairs fCG/GCf were cleaved with the formation of 14 bp
fluorescent products, the reaction mixtures were analyzed in 20% PAG with 7 M urea (Figure 4A,B).
The time courses of methylation of the DNA substrate fCG/GCf by WT and mutant Dnmt3a-CD were
obtained (Figure 4C). The curves were linear until 5 and 10 min for WT Dnmt3a-CD and mutants,
respectively. In the case of R45W, R146H, and F162V, methylation activity was abolished. The initial
rates of methylation (v0) were determined (Table 3). The efficiency of methylation (v0rel, Table 3) for
S124C and P187R was 2.6- and 14-fold, respectively, lower than for the WT Dnmt3a-CD.
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Table 3. Methylation activity, DNA binding affinity, Dnmt3L activation, and covalent complex formation
with 2-pyrimidinone-substituted DNA duplex fCG/GZ by WT and mutant Dnmt3a-CD. Data represent
the results from at least three independent experiments.
Exchange v0, nM/min** v0
rel, % Kd, nM Kdrel
Ability of
Dnmt3L to
Enhance
Dnmt3a
Functionality
Covalent
Complex
Formation
with
fCG/GZ
WT 15.7 ± 1 100 77 ± 6 1.00 Yes Yes
S124C 6.2 ± 4 39 127 ± 44 1.63 Yes Yes
R146H
No activity No activity No binding No binding No n.d.*
R45W
F162V 232 ± 32 3.01 No No
P187R 1.1 ± 1 7 n.d. * n.d. * No No
* n.d.–not determined, ** the same concentration of WT or mutant Dnmt3a was used in each experiment.
Further, to examine the methylation activities for the low activity mutants, the total time of the
reaction was increased up to 2 h, the other conditions being the same. The extent of methylation (M) for
each enzyme relative to WT was determined (Figure 5A). The M values for S124C, R181L, and P187R
were 1.6-, 2-, 20-fold lower, respectively, compared to the WT Dnmt3a-CD. R45W, R146H, and F162V
showed practically no methylation activity.
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Figure 5. Methylation by WT and mutant Dnmt3a-CD in the presence or absence of Dnmt3L during
2 h. (a) Reaction mixtures contai ed 0.3 µM fCG/GCf NA substrate, 2 µM Dnmt3a-CD or mutant,
and 25 µM AdoMet; data represent the averaged results from at least six independent experi ents;
(b) Reaction mixtures cont ined 120 nM fCG/GCf DNA substrate, 1 µM WT or mutant Dnmt3a-CD,
and 1 µM Dnmt3L; data represent the averaged results from three independent experiments.
The ability of enzymatically inactive regulatory factor Dnmt3L to activate WT and mutant Dnmt3a-CD
was examined (Figure 5B). Dnmt3a-CD in complex with Dnmt3L f rms a linear heterotetr mer consisting of
two Dnmt3a-CD and two Dnmt3L subunits [34]. Dnm 3L p sitions the Dnmt3a catalyt c loop and improves
the catalysis [3]. Th Dnmt3L caus d a 1.3–4.2-fold ncrease in WT and S124C methylation activity and did
not a tivate P187R and enzymatically inactive mutants R146H, F162V, and R45W.
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Our results allow us to highlight mutations that lead to a decrease (S124C and P187R) or loss
(R146H, F162V, and R45W) of methylation activity. To understand the mechanism underlying these
phenomena, several steps of methylation reaction were investigated. The DNA methylation reaction
mechanism included the following steps: DNA recognition and binding, target cytosine flipping out of
the double helix, attack of the conserved cysteine at C6 position and covalent intermediate formation,
methyl group transfer from the donor AdoMet, followed by resolution of the intermediate and release
of the products [3,35]. Then the binding step and the formation of the covalent intermediate were
analyzed in detail.
3.3. DNA Binding
Dnmt3a-CD/DNA complex formation was monitored by fluorescence polarization of FAM-labeled
DNA using a one-site DNA substrate fCG/CG (Table 2). Binding measurements were performed
in the presence of the co-factor analog AdoHcy, which mimics the experimental conditions of the
methylation assays [36]. For WT and S124C, nearly hyperbolic binding curves were obtained (Figure 6).
For P187R and F162V, no plateau on the curves was observed due to a low concentration of the purified
enzymes (Figure 6, insert). Surprisingly, R45W and R146H showed no binding to DNA. All the data
obtained were analyzed according to the Hill model with a 3-parameter Hill equation considering the
cooperative nature of binding of Dnmt3a-CD to DNA [37]. The Kd value for the WT was 77 ± 6 nM;
the Kd values for S124C and F162V were 1.6–3-fold higher relative to the WT (Table 3). The Kd value
for P187R was not determined. However, the enzyme retained the weak ability to bind DNA.
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Overall, the S124C, F162V, and P187R mutations did not affect the ability of Dnmt3a to bind DNA,
but R45W and R146H mutations lead to a complete loss of the DNA binding affinity.
3.4. Formation of Covalent Intermediates between Dnmt3a-CD and DNA Duplexes Containing 2-Pyrimidinone
One f the key steps of the DNA methylation reaction is the formation of the transient covalent
complex between the enzyme and its DNA substrate [37]. The FAM-labeled one-site 18 bp DNA
substrate fCG/GZ containing 2-pyrimidinone (Z) in the place of the target cytosine was used (Table 2).
The nucleophilic attack by the highly conserved cysteine of the motif IV at the C6 position of the
cytosine ring produces the covalent conjugate, which triggers the subsequent methyl group transfer
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from AdoMet to the C5 carbon atom [37]. The covalent complex is resolved by deprotonation at C5
leading to β-elimination of the cysteine residue [3]. Conjugates of C5-MTases with DNA containing Z
instead of the target cytosine are stable due to the retardation of β-elimination and can be detected by
gel electrophoresis [38]. The ability of WT Dnmt3a-CD and mutants to form a covalent conjugate was
analyzed in the presence of co-factor AdoHcy. The covalent conjugate formation was observed only
for S124C (Figure 7) but not for the P187R and the F162V (data not shown).
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One can conclude that the mutations can be divided into several groups. The first group includes
only the S124C mutation, which led to a significant decrease in Dnmt3a-CD methylation activity.
The second group consists of mutations, such as F162V and P187R, which reduced methylation activity
even in the presence of Dnmt3L but do not affect the ability of enzymes to bind DNA. Moreover,
mutations that led to a drastic change in Dnmt3a-CD functioning in all aspects (R45W and R146H)
form the third category. The results obtained indicated that all the substituted amino acid residues are
important for the proper Dnmt3a-CD functioning.
4. Discussion
To determine the functional consequences of missense mutations in DNMT3A, we selected six
mutations in the catalytic domain of murine Dnmt3a: S124C, R45W, R146H, R181L, P187R, and F162V.
Figure 8 highlights the positions of the mutated amino acid residues in the structures of Dnmt3a-CD [25]
and DNA-(DNMT3A)-DNMT3L complex (PDB code: 6F57) [30].
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in magenta. Residues of inter t within human DNMT3A-CD are numbered in accordance with murine
Dnmt3a-CD and given in red.
S124 (714) is one of the highly conserved amino acids of the motif IV (Figure 2), which is located in
the catalytic loop (Figure 8) [30]. Replacement of S124 with cysteine reduced the activity of Dnmt3a-CD
(v0rel va ue decreased threefold), but only slightly affected the DNA binding affinity (Kd increased
1.6-fold). ur data are in accordance ith recent studies sho ing the decreased enzy e activity of
the hu an T3 S714 utant [29,30]. In human DNMT3A, the S714 residue participates in
the formation of electrostatic interactions between the sugar-phosphate backbone and MTase [30].
We suggest that S124 acts as a “hinge” that facilitates the flipping of target cytosine residue out of
the DNA helix. Thus, we analyzed the formation of the transient covalent complex between S124C
and DNA containing 2-pyrimidinone in place of the target cytosine (f / ). onsistent ith our
predictions, the complex was less prominent compared to that of WT (Figure 7). This step is supposed
to be coupled ith the flipping of the target cytosine [39]. long ith that, S124 as significantly
sti ulate by activator n t3 ( able 3). ollectively, the negative effect of S124C utation can be
considered oderate.
The R45 (635) is located within the conserved motif I predicted for AdoMet binding (Figure 2) and
far away from the Dnmt3a/3L interface [3] (Figure 8). Replacing R45 with tryptophan led to a complete
loss of the enzyme activity (Table 3). Similarly, the R635G DNMT3A demonstrate the decrease in
methylation activity on the poly dI-dC substrate [29]. In the case of R45W, we observed a complete
loss of DNA binding affinity and a lack of activation by Dnmt3L. It is possible that R45W might affect
protein structure and stability.
Even though R146H (736), F162V (752), and P187R (777) residues are not the highly conserved
across the functional motives I-X of Dnmt3a (Figure 2), we observed a strong impact of these mutations
on the methylation reaction (Table 3).
Replacing R146 with histidine led to a complete loss of Dnmt3a-CD methylation activity
accompanied by the loss of DNA binding affinity and the absence of activation by Dnmt3L (Table 3).
Our data are in accordance with a report demonstrating that the R736A mutation leads to the 20-fold
decrease in methylation activity [28]. Recent studies on human R736H DNMT3A have shown the
hypermethylation of long multi-CpG DNA substrate (749 bp) and the decrease in methylation activity
on the poly dI-dC substrate [29]. Based on these findings, we can suggest the dependence of R146H
methylation activity on the DNA substrate. According to the DNA-(DNMT3A)-DNMT3L co-crystal
structure, the R146 residue is located within the tetramer interface (Figure 8) [28]. We speculate that
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R146H mutation disturbed the tetramer interface, similarly to the R882H/C mutation [40], which led to
the loss of binding affinity.
Replacement of P187 with arginine and F162 with valine led to a 15-fold decrease or to a complete
loss of the methylation activity, respectively (Table 3). Both mutants preserved the ability to bind
DNA, but the Kd values were at least three times higher than that for the WT. Notably, we did not
observe the formation of a transient covalent complex of P187R or F162V with fCG/GZ, and the Dnmt3L
activator protein did not increase their methylation activities. The P187 residue is located within the loop
connecting the α-helix and the β-sheet (Figure 8) in the hydrophobic core, which consists of aliphatic
(Val, Ile, Met) and aromatic (Tyr) amino acids and is located near the positively charged Lys residue. Due
to its cyclic structure, proline bestows local rigidity to the enzyme structure, fixing α-helix and β-sheet
positions relative to each other. Replacement of proline with arginine may lead to a conflict between the
environment and the charged arginine residue. At the same time, this replacement increases local chain
mobility. Together, these changes may result in a critical disruption of the enzyme’s tertiary structure.
The F162 residue is located near motif VI (ENV). The F162V mutation likely creates a steric clash that
can affect the interaction of the ENV tripeptide with the target cytosine residue and lead to the loss of
enzymatic activity.
5. Conclusions
We studied the effect of five missense mutations in the human DNMT3A catalytic domain found
in AML patients. Considering the dramatic decrease in methylation of mutated Dnmt3a-CD, one can
suggest functional impairment of DNMT3A during AML progression. We examined the individual
steps of the methylation reaction, which may be disturbed due to the mutations. Surprisingly, in the
case of R45W and R146H enzymes, the ability to bind DNA was abolished. We believe that these
cancer-associated mutations may result in the change of the methylation patterns. Interestingly, in
the case of R45W mutation in the AdoMet binding region, the loss of ability to bind DNA was found.
The in vitro results can act as a basis for further in vivo analyses, as they are useful for understanding
the presence of the aberrant methylation pattern characteristic for AML [17]. Mutated variants of
DNMT3A can act as new biomarkers important for developing effective individual therapy and may
become attractive targets for personalized medicine.
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Figure A1. R181L Western blot. Lane 1 represents the protein ladder; Lanes 2 and 3 represent protein 
dilution 1:10 and 1:15, respectively. Fifteen percent PAG with 10% SDS, 1:5000 mouse HRP 
monoclonal anti-His6-tag antibodies. Molecular mass of the Dnmt3a-CD 37 kDa, the expected second 
lane of 20 kDa is not observed. 
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